BioVie’s Bezisterim Improves Parkinson’s Symptoms in Phase 2 Trial Subgroup With Higher Inflammation

PUBT · 6d ago
BioVie’s Bezisterim Improves Parkinson’s Symptoms in Phase 2 Trial Subgroup With Higher Inflammation
  • BioVie will present additional bezisterim findings from its Phase 2 SUNRISE-PD trial at AD/PD2027 in Barcelona on March 20, 2027.
  • The randomized, placebo-controlled trial evaluated 57 patients with early Parkinson's disease over 12 weeks.
  • Patients with higher baseline inflammation showed the strongest response, with significant improvements in motor and non-motor symptoms compared with placebo.
  • Overall results favored bezisterim, with treated patients more likely to achieve meaningful clinical improvement and less likely to worsen than placebo recipients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100800PRIMZONEFULLFEED9873969) on November 10, 2026, and is solely responsible for the information contained therein.